{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:22:41Z","timestamp":1793330561642,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1038\/s41375-020-0789-x","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T19:06:30Z","timestamp":1584471990000},"page":"3242-3255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Existence of reprogrammed lymphoma stem cells in a murine ALCL-like model"],"prefix":"10.1038","volume":"34","author":[{"given":"Stefanie","family":"Kreutmair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathrin","family":"Klingeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Poggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffroy","family":"Andrieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4699-3805","authenticated-orcid":false,"given":"Cornelius","family":"Miething","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Follo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Shoumariyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-2805","authenticated-orcid":false,"given":"Claudia","family":"Lengerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Gonzalez-Menendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5496-293X","authenticated-orcid":false,"given":"Falko","family":"Fend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8439-4507","authenticated-orcid":false,"given":"Suzanne D.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Quintanilla-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3670-0602","authenticated-orcid":false,"given":"Melanie","family":"Boerries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus","family":"Duyster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Illert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,17]]},"reference":[{"key":"789_CR1","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1182\/blood-2008-08-077941","volume":"112","author":"JE Dick","year":"2008","unstructured":"Dick JE. Stem cell concepts renew cancer research. Blood. 2008;112:4793\u2013807.","journal-title":"Blood"},{"key":"789_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nm.2304","volume":"17","author":"H Clevers","year":"2011","unstructured":"Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17:313\u20139.","journal-title":"Nat Med"},{"key":"789_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","volume":"14","author":"A Kreso","year":"2014","unstructured":"Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14:275\u201391.","journal-title":"Cell Stem Cell"},{"key":"789_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/35102167","volume":"414","author":"T Reya","year":"2001","unstructured":"Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105\u201311.","journal-title":"Nature"},{"key":"789_CR5","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nm.4409","volume":"23","author":"E Batlle","year":"2017","unstructured":"Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23:1124\u201334.","journal-title":"Nat Med"},{"key":"789_CR6","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"789_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature05372","volume":"445","author":"CA O\u2019Brien","year":"2007","unstructured":"O\u2019Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106\u201310.","journal-title":"Nature"},{"key":"789_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature05384","volume":"445","author":"L Ricci-Vitiani","year":"2007","unstructured":"Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111\u20135.","journal-title":"Nature"},{"key":"789_CR9","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature03128","volume":"432","author":"SK Singh","year":"2004","unstructured":"Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396\u2013401.","journal-title":"Nature"},{"key":"789_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645\u20138.","journal-title":"Nature"},{"key":"789_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13045-015-0161-1","volume":"8","author":"R Mathur","year":"2015","unstructured":"Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, et al. Targeting Wnt pathway in mantle cell lymphoma-initiating cells. J Hematol Oncol. 2015;8:63.","journal-title":"J Hematol Oncol"},{"key":"789_CR12","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1200\/JCO.2008.21.5020","volume":"27","author":"C Laurent","year":"2009","unstructured":"Laurent C, Do C, Gascoyne RD, Lamant L, Ysebaert L, Laurent G, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol. 2009;27:4211\u20136.","journal-title":"J Clin Oncol"},{"key":"789_CR13","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1182\/blood.V66.4.848.848","volume":"66","author":"H Stein","year":"1985","unstructured":"Stein H, Mason DY, Gerdes J, O\u2019Connor N, Wainscoat J, Pallesen G, et al. The expression of the Hodgkin\u2019s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848\u201358.","journal-title":"Blood"},{"key":"789_CR14","doi-asserted-by":"publisher","first-page":"8611","DOI":"10.1158\/0008-5472.CAN-09-2655","volume":"69","author":"C Ambrogio","year":"2009","unstructured":"Ambrogio C, Martinengo C, Voena C, Tondat F, Riera L, di Celle PF, et al. NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res. 2009;69:8611\u20139.","journal-title":"Cancer Res"},{"key":"789_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1182\/blood-2016-05-717793","volume":"129","author":"MT Werner","year":"2017","unstructured":"Werner MT, Zhao C, Zhang Q, Wasik MA. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target. Blood. 2017;129:823\u201331.","journal-title":"Blood"},{"key":"789_CR16","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41375-018-0239-1","volume":"33","author":"N Prutsch","year":"2019","unstructured":"Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, et al. Dependency on the TYK2\/STAT1\/MCL1 axis in anaplastic large cell lymphoma. Leukemia. 2019;33:696\u2013709.","journal-title":"Leukemia"},{"key":"789_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/path.4539","volume":"236","author":"O Merkel","year":"2015","unstructured":"Merkel O, Hamacher F, Griessl R, Grabner L, Schiefer AI, Prutsch N, et al. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. J Pathol. 2015;236:445\u201356.","journal-title":"J Pathol"},{"key":"789_CR18","doi-asserted-by":"crossref","unstructured":"Garces de Los Fayos Alonso I, Liang HC, Turner SD, Lagger S, Merkel O, Kenner L. The role of activator protein-1 (AP-1) family members in CD30-positive lymphomas. Cancers. 2018;10.","DOI":"10.3390\/cancers10040093"},{"key":"789_CR19","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/labinvest.2017.39","volume":"97","author":"SR Hwang","year":"2017","unstructured":"Hwang SR, Murga-Zamalloa C, Brown N, Basappa J, McDonnell SR, Mendoza-Reinoso V, et al. Pyrimidine tract-binding protein 1 mediates pyruvate kinase M2-dependent phosphorylation of signal transducer and activator of transcription 3 and oncogenesis in anaplastic large cell lymphoma. Lab Investig; a J Tech methods Pathol. 2017;97:962\u201370.","journal-title":"Lab Investig; a J Tech methods Pathol"},{"key":"789_CR20","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/s41388-019-1058-1","volume":"39","author":"K Shoumariyeh","year":"2019","unstructured":"Shoumariyeh K, Schneider N, Poggio T, Veratti P, Ehrenfeld S, Redhaber DM, et al. A novel conditional NPM-ALK-driven model of CD30+ T-cell lymphoma mediated by a translational stop cassette. Oncogene 2019;39:1904\u201313.","journal-title":"Oncogene"},{"key":"789_CR21","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/leu.2014.283","volume":"29","author":"AL Illert","year":"2015","unstructured":"Illert AL, Albers C, Kreutmair S, Leischner H, Peschel C, Miething C, et al. Grb10 is involved in BCR-ABL-positive leukemia in mice. Leukemia. 2015;29:858\u201368.","journal-title":"Leukemia"},{"key":"789_CR22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00018-018-2952-3","volume":"76","author":"D Ewerth","year":"2019","unstructured":"Ewerth D, Kreutmair S, Schmidts A, Ihorst G, Follo M, Wider D, et al. APC\/C(Cdh1) regulates the balance between maintenance and differentiation of hematopoietic stem and progenitor cells. Cell Mol life Sci. 2019;76:369\u201380.","journal-title":"Cell Mol life Sci"},{"key":"789_CR23","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/leu.2017.267","volume":"32","author":"S Gerboth","year":"2018","unstructured":"Gerboth S, Frittoli E, Palamidessi A, Baltanas FC, Salek M, Rappsilber J, et al. Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis. Leukemia. 2018;32:820\u20137.","journal-title":"Leukemia"},{"key":"789_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1182\/blood.2018883140","volume":"134","author":"A Rudorf","year":"2019","unstructured":"Rudorf A, Muller TA, Klingeberg C, Kreutmair S, Poggio T, Gorantla SP, et al. NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia. Blood. 2019;134:383\u20138.","journal-title":"Blood"},{"key":"789_CR25","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/leu.2016.72","volume":"30","author":"TA Muller","year":"2016","unstructured":"Muller TA, Grundler R, Istvanffy R, Rudelius M, Hennighausen L, Illert AL, et al. Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype. Leukemia. 2016;30:1725\u201333.","journal-title":"Leukemia"},{"key":"789_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1084\/jem.20150556","volume":"213","author":"C Klein","year":"2016","unstructured":"Klein C, Zwick A, Kissel S, Forster CU, Pfeifer D, Follo M, et al. Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression. J Exp Med. 2016;213:273\u201390.","journal-title":"J Exp Med"},{"key":"789_CR27","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","volume":"130","author":"B Pro","year":"2017","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130:2709\u201317.","journal-title":"Blood"},{"key":"789_CR28","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1158\/1535-7163.MCT-11-0042","volume":"10","author":"O Merkel","year":"2011","unstructured":"Merkel O, Hamacher F, Sifft E, Kenner L, Greil R. Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools. Mol cancer therapeutics. 2011;10:1127\u201336.","journal-title":"Mol cancer therapeutics"},{"key":"789_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229\u201340.","journal-title":"Lancet"},{"key":"789_CR30","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853\u201362.","journal-title":"Lancet"},{"key":"789_CR31","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","volume":"132","author":"CH Moskowitz","year":"2018","unstructured":"Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132:2639\u201342.","journal-title":"Blood"},{"key":"789_CR32","doi-asserted-by":"publisher","first-page":"7628","DOI":"10.1158\/0008-5472.CAN-05-0925","volume":"65","author":"M Watanabe","year":"2005","unstructured":"Watanabe M, Sasaki M, Itoh K, Higashihara M, Umezawa K, Kadin ME, et al. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1\/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res. 2005;65:7628\u201334.","journal-title":"Cancer Res"},{"key":"789_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.85","volume":"7","author":"CA van der Weyden","year":"2017","unstructured":"van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J. 2017;7:e603.","journal-title":"Blood Cancer J"},{"key":"789_CR34","doi-asserted-by":"crossref","unstructured":"Montes-Mojarro IA, Steinhilber J, Bonzheim I, Quintanilla-Martinez L, Fend F The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL). Cancers 2018;10.","DOI":"10.3390\/cancers10040107"},{"key":"789_CR35","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1182\/bloodadvances.2017008854","volume":"1","author":"S Husby","year":"2017","unstructured":"Husby S, Gronbaek K. Mature lymphoid malignancies: origin, stem cells, and chronicity. Blood Adv. 2017;1:2444\u201355.","journal-title":"Blood Adv"},{"key":"789_CR36","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/onc.2014.112","volume":"34","author":"N Moti","year":"2015","unstructured":"Moti N, Malcolm T, Hamoudi R, Mian S, Garland G, Hook CE, et al. Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin. Oncogene. 2015;34:1843\u201352.","journal-title":"Oncogene"},{"key":"789_CR37","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.celrep.2016.09.018","volume":"17","author":"MR Hassler","year":"2016","unstructured":"Hassler MR, Pulverer W, Lakshminarasimhan R, Redl E, Hacker J, Garland GD, et al. Insights into the pathogenesis of anaplastic large-cell lymphoma through genome-wide DNA methylation profiling. Cell Rep. 2016;17:596\u2013608.","journal-title":"Cell Rep."},{"key":"789_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10087","volume":"7","author":"TI Malcolm","year":"2016","unstructured":"Malcolm TI, Villarese P, Fairbairn CJ, Lamant L, Trinquand A, Hook CE, et al. Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress. Nat Commun. 2016;7:10087.","journal-title":"Nat Commun"},{"key":"789_CR39","doi-asserted-by":"crossref","unstructured":"Malcolm TI, Hodson DJ, Macintyre EA, Turner SD. Challenging perspectives on the cellular origins of lymphoma. Open Biology 2016;6.","DOI":"10.1098\/rsob.160232"},{"key":"789_CR40","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.4049\/jimmunol.1302259","volume":"192","author":"DK Shah","year":"2014","unstructured":"Shah DK, Zuniga-Pflucker JC. An overview of the intrathymic intricacies of T cell development. J Immunol. 2014;192:4017\u201323.","journal-title":"J Immunol"},{"key":"789_CR41","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood-2002-05-1343","volume":"101","author":"R Chiarle","year":"2003","unstructured":"Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood. 2003;101:1919\u201327.","journal-title":"Blood"},{"key":"789_CR42","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ijpharm.2019.04.013","volume":"564","author":"X Luo","year":"2019","unstructured":"Luo X, Yang Y, Kong F, Zhang L, Wei K. CD30 aptamer-functionalized PEG-PLGA nanoparticles for the superior delivery of doxorubicin to anaplastic large cell lymphoma cells. Int J Pharm. 2019;564:340\u20139.","journal-title":"Int J Pharm"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0789-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0789-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0789-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T11:04:57Z","timestamp":1723460697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0789-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,17]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0789-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,17]]},"assertion":[{"value":"20 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}